GlassScriptPhysician profile
Robert Gordon Skwerer
NPI 1184683799
$5,742.43
in general payments reported to CMS, 2019-2025
23 companies · $1,998 in 2025
The $1,998 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $54.59 · 2023: $1,529 · 2024: $2,160 · 2025: $1,998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,676 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,675.69 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,391.61 | 2023-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $615.93 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $515.78 | 2023-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $385.51 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $336.31 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $317.84 | 2022-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $304.34 | 2024-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $287.76 | 2023-2025 | Rexulti |
| Bausch Health US, LLC | $251.84 | 2023-2025 | Aplenzin, Wellbutrin |
| Teva Pharmaceuticals USA, INC. | $201.65 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Tris Pharma INC | $154.20 | 2023-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $148.79 | 2023-2025 | Trintellix |
| Indivior INC. | $148.22 | 2023-2025 | Sublocade |
| Axsome Therapeutics, INC. | $140.35 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $126.44 | 2024-2025 | Cobenfy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $80.80 | 2023-2024 | Quviviq |
| Noven Therapeutics, LLC | $72.11 | 2023-2024 | Xelstrym, Secuado |
| Braeburn INC. | $51.55 | 2024 | Brixadi |
| Corium, LLC | $50.94 | 2023-2024 | Azstarys |
| Validus Pharmaceuticals LLC | $47.29 | 2024 | Equetro |
| Ironshore Pharmaceuticals INC. | $45.65 | 2023 | Jornay Pm |
| Neos Therapeutics, LP | $45.27 | 2023-2024 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $22.25 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Skwerer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.